Related references
Note: Only part of the references are listed.From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
Morvane Colin et al.
ACTA NEUROPATHOLOGICA (2020)
Measuring biological aging in humans: A quest
Luigi Ferrucci et al.
AGING CELL (2020)
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders
Anne Messer et al.
NEUROBIOLOGY OF DISEASE (2020)
Advances and considerations in AD tau-targeted immunotherapy
Alice Bittar et al.
NEUROBIOLOGY OF DISEASE (2020)
Characterization of novel conformation-selective alpha-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease
Michael X. Henderson et al.
NEUROBIOLOGY OF DISEASE (2020)
Aging: therapeutics for a healthy future
Robert Hodgson et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2020)
NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy
Rachael H. Earls et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
Junghwan Shin et al.
JOURNAL OF MOVEMENT DISORDERS (2020)
Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons
Rik van der Kant et al.
CELL STEM CELL (2019)
Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology
Silvia Pozzi et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Transmission of α-synuclein seeds in neurodegenerative disease: recent developments
Richard J. Karpowicz et al.
LABORATORY INVESTIGATION (2019)
Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy
Yevgen Chornenkyy et al.
LABORATORY INVESTIGATION (2019)
In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies
Veronika Hanko et al.
NEUROBIOLOGY OF AGING (2019)
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
Alberto J. Espay et al.
NEUROLOGY (2019)
Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice
Giovanna De Chiara et al.
PLOS PATHOGENS (2019)
α-Synuclein: A Multifunctional Player in Exocytosis, Endocytosis, and Vesicle Recycling
Mingzhu Huang et al.
FRONTIERS IN NEUROSCIENCE (2019)
Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors
Stephen S. Dominy et al.
SCIENCE ADVANCES (2019)
Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody
Marie Albert et al.
BRAIN (2019)
How is alpha-synuclein cleared from the cell?
Leonidas Stefanis et al.
JOURNAL OF NEUROCHEMISTRY (2019)
Association of statin use with Parkinson's disease: Dose-response relationship
Su-Min Jeong et al.
MOVEMENT DISORDERS (2019)
Alzheimer disease and aducanumab: adjusting our approach
Dennis J. Selkoe
NATURE REVIEWS NEUROLOGY (2019)
An Overview of Primary Dementias as Clinicopathological Entities
Arash Salardini
SEMINARS IN NEUROLOGY (2019)
Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy
Balvindar Singh et al.
ACTA NEUROPATHOLOGICA (2019)
Progress of immunotherapy of anti-α-synuclein in Parkinson's disease
Zhipeng Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Could changing the course of Alzheimer's disease pathology with immunotherapy prevent dementia?
Cassia Overk et al.
BRAIN (2019)
Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease
James A. R. Nicoll et al.
BRAIN (2019)
IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease
Zhan Liu et al.
BRAIN BEHAVIOR AND IMMUNITY (2019)
Blood Pressure and Statin Effects on Cognition: a Review
Mia Yang et al.
CURRENT HYPERTENSION REPORTS (2019)
α-synuclein in the pathophysiology of Alzheimer's disease
Daniel Twohig et al.
MOLECULAR NEURODEGENERATION (2019)
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054
Miroslaw Brys et al.
MOVEMENT DISORDERS (2019)
Four-repeat tauopathies
Thomas W. Roesler et al.
PROGRESS IN NEUROBIOLOGY (2019)
Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease
Takuya Uehara et al.
SCIENTIFIC REPORTS (2019)
The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration
Taxiarchis Katsinelos et al.
FRONTIERS IN IMMUNOLOGY (2019)
Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model
Markus Mandler et al.
ALZHEIMERS & DEMENTIA (2019)
The neuropathological diagnosis of Alzheimer's disease
Michael A. DeTure et al.
MOLECULAR NEURODEGENERATION (2019)
Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans
Petronela Weisova et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Fresh push for ‘failed’ Alzheimer’s drug
Alison Abbott
NATURE (2019)
Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies
Somin Kwon et al.
EXPERIMENTAL NEUROBIOLOGY (2019)
Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice
Takashi Mori et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
A critical appraisal of amyloid-βtargeting therapies for Alzheimer disease
Francesco Panza et al.
NATURE REVIEWS NEUROLOGY (2019)
Gene Therapy for Neurodegenerative Diseases
Vivek Sudhakar et al.
NEUROTHERAPEUTICS (2019)
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
Darren J. Schofield et al.
NEUROBIOLOGY OF DISEASE (2019)
Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice
Hayk Davtyan et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
2019 Alzheimer's disease facts and figures
Joseph Gaugler et al.
ALZHEIMERS & DEMENTIA (2019)
Molecular mechanisms of proteinopathies across neurodegenerative disease: a review
Alexander P. Marsh
NEUROLOGICAL RESEARCH AND PRACTICE (2019)
Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies
Edward Rockenstein et al.
JOURNAL OF NEUROSCIENCE (2018)
Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons
Shahzad S. Khan et al.
ACTA NEUROPATHOLOGICA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Person-Specific Contribution of Neuropathologies to Cognitive Loss in Old Age
Patricia A. Boyle et al.
ANNALS OF NEUROLOGY (2018)
alpha-Synuclein Oligomers Induce a Unique Toxic Tau Strain
Diana L. Castillo-Carranza et al.
BIOLOGICAL PSYCHIATRY (2018)
Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated
John L. Robinson et al.
BRAIN (2018)
Mechanisms of protein toxicity in neurodegenerative diseases
Chang Geon Chung et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Systematic review of the efficacy of statins for the treatment of Alzheimer's disease
Marta Mejias-Trueba et al.
CLINICAL MEDICINE (2018)
Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer's disease
Alpdogan Kantarci et al.
EXPERIMENTAL NEUROLOGY (2018)
Dale Schenk One Year Anniversary: Fighting to Preserve the Memories
Cassia Overk et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia
Aradhana Sahoo et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Herpes Zoster and Dementia: A Nationwide Population-Based Cohort Study
Vincent Chin-Hung Chen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2018)
Passive A Immunotherapy: Current Achievements and Future Perspectives
Stephan Schilling et al.
MOLECULES (2018)
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Victor L. Villemagne et al.
NATURE REVIEWS NEUROLOGY (2018)
Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan
Nian-Sheng Tzeng et al.
NEUROTHERAPEUTICS (2018)
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S. Honig et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis
Che-Sheng Chu et al.
SCIENTIFIC REPORTS (2018)
Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals
Yoshitaka Tamaki et al.
SCIENTIFIC REPORTS (2018)
Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial
Ana-Maria Lacosta et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic et al.
JAMA NEUROLOGY (2018)
Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies
Ian F. Caplan et al.
FRONTIERS IN PHARMACOLOGY (2018)
Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies
Alice Bittar et al.
NPJ VACCINES (2018)
Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau
Jean-Philippe Courade et al.
ACTA NEUROPATHOLOGICA (2018)
Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
Changyoun Kim et al.
MOLECULAR NEURODEGENERATION (2018)
Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age
Oeystein R. Brekk et al.
SCIENTIFIC REPORTS (2018)
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease
Diana L. Price et al.
SCIENTIFIC REPORTS (2018)
Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice
Francesca Vitale et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection (vol 99, pg 56, 2018)
William A. Eimer et al.
NEURON (2018)
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease
Petr Novak et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Petr Novak et al.
FRONTIERS IN NEUROSCIENCE (2018)
The relevance of cerebrospinal fluid -synuclein levels to sporadic and familial Alzheimer's disease
Daniel Twohig et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer's disease
Wenguang Chang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model
Diptaman Chatterjee et al.
NPJ PARKINSONS DISEASE (2018)
Prevalence of Parkinson's disease across North America
C. Marras et al.
NPJ PARKINSONS DISEASE (2018)
Elevated Epstein-Barr Virus Antibody Level is Associated with Cognitive Decline in the Korean Elderly
Sung-Mi Shim et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology
David H. Adamowicz et al.
JOURNAL OF NEUROSCIENCE (2017)
Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents
Marie Jouanne et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Identification of senescent cell surface targetable protein DPP4
Kyoung Mi Kim et al.
GENES & DEVELOPMENT (2017)
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
David Irwin et al.
LANCET NEUROLOGY (2017)
Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide
Maria Gregori et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Randomized controlled trials in mild cognitive impairment Sources of variability
Ronald C. Petersen et al.
NEUROLOGY (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impact of aging immune system on neurodegeneration and potential immunotherapies
Zhanfeng Liang et al.
PROGRESS IN NEUROBIOLOGY (2017)
Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy
Kiran Yanamandra et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
Sarah L. DeVos et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Pathology of Neurodegenerative Diseases
Brittany N. Dugger et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
Susanne Ostrowitzki et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Tau passive immunization inhibits not only tau but also Aβ pathology
Chun-ling Dai et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases
Helene-Marie Lanoiselee et al.
PLOS MEDICINE (2017)
Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease
Julie M. Zissimopoulos et al.
JAMA NEUROLOGY (2017)
Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy
Elvira Valera et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
Brian Spencer et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model
Randall J. Bateman et al.
ALZHEIMERS & DEMENTIA (2017)
Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology
Jon B. Toledo et al.
ACTA NEUROPATHOLOGICA (2016)
Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis
Shinji Matsunaga et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies
Anna Villar-Pique et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Combination therapies: The next logical Step for the treatment of synucleinopathies?
Elvira Valera et al.
MOVEMENT DISORDERS (2016)
Cortical Lewy bodies and Ab burden are associated with prevalence and timing of dementia in Lewy body diseases
C. Ruffmann et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2016)
Immunotherapeutic Approaches Targeting Amyloid-beta, alpha-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
Elvira Valera et al.
NEUROTHERAPEUTICS (2016)
Updated TDP-43 in Alzheimer's disease staging scheme
Keith A. Josephs et al.
ACTA NEUROPATHOLOGICA (2016)
Recent advances of cocktail chemotherapy by combination drug delivery systems
Quanyin Hu et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Temporal Cognitive Decline Associated With Exposure to Infectious Agents in a Population-based, Aging Cohort
Vishwajit L. Nimgaonkar et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2016)
Gene therapy to target ER stress in brain diseases
Vicente Valenzuela et al.
BRAIN RESEARCH (2016)
ER stress and Parkinson's disease: Pathological inputs that converge into the secretory pathway
Gabriela Mercado et al.
BRAIN RESEARCH (2016)
Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials
Sevil Yasar et al.
CURRENT HYPERTENSION REPORTS (2016)
The amyloid hypothesis of Alzheimer's disease at 25years
Dennis J. Selkoe et al.
EMBO MOLECULAR MEDICINE (2016)
α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease
Brian Spencer et al.
HUMAN MOLECULAR GENETICS (2016)
Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials
Richard E. Kennedy et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease
Florence Pasquier et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice
Wencheng Liu et al.
JOURNAL OF NEUROSCIENCE (2016)
Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model
Brian Spencer et al.
JOURNAL OF NEUROSCIENCE (2016)
Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy
Erin E. Congdon et al.
MOLECULAR NEURODEGENERATION (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody
Veronika Logovinsky et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease
Brian Spencer et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease
Lars Tatenhorst et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2016)
Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?
Andrea L. J. Marschall et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2016)
Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
Mark Ultsch et al.
SCIENTIFIC REPORTS (2016)
Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes
Lauren Walker et al.
ACTA NEUROPATHOLOGICA (2015)
被撤回的出版物: β-Amyloid and α-Synuclein Cooperate To Block SNARE-Dependent Vesicle Fusion(Retracted article. See vol. 56, pg.1026,2017)
Bong-Kyu Choi et al.
BIOCHEMISTRY (2015)
Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer's Disease: Results from Two Phase 2 Studies
Heii Arai et al.
CURRENT ALZHEIMER RESEARCH (2015)
EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease
R. Schmidt et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Building a roadmap for developing combination therapies for Alzheimer's disease
Daniel Perry et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model
Alevtina D. Zharikov et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Porphyromonas gingivalis Periodontal Infection and Its Putative Links with Alzheimer's Disease
Sim K. Singhrao et al.
MEDIATORS OF INFLAMMATION (2015)
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
Markus Mandler et al.
MOLECULAR NEURODEGENERATION (2015)
RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration
Diego Peretti et al.
NATURE (2015)
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Rebecca C. Coll et al.
NATURE MEDICINE (2015)
Inhibition of amyloid-β plaque formation by α-synuclein
Teresa Bachhuber et al.
NATURE MEDICINE (2015)
Spreading of pathology in neurodegenerative diseases: a focus on human studies
Johannes Brettschneider et al.
NATURE REVIEWS NEUROSCIENCE (2015)
Human secreted tau increases amyloid-beta production
Jessica Bright et al.
NEUROBIOLOGY OF AGING (2015)
Immunotherapeutic Approaches for Alzheimer's Disease
Thomas Wisniewski et al.
NEURON (2015)
Tailoring the Antibody Response to Aggregated Aβ Using Novel Alzheimer-Vaccines
Markus Mandler et al.
PLOS ONE (2015)
Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy
Changyoun Kim et al.
CELL REPORTS (2015)
Building a roadmap for developing combination therapies for Alzheimer's disease
Daniel Perry et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias
David R. Howlett et al.
BRAIN PATHOLOGY (2015)
Anti-Human α-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-α-Synuclein Rat Model of Parkinson's Disease
Md Shahaduzzaman et al.
PLOS ONE (2015)
Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease
Claude M. Wischik et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials
Markus Mandler et al.
ACTA NEUROPATHOLOGICA (2014)
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Cassia R. Overk et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease
Ashley R. Winslow et al.
BRAIN (2014)
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
Dora Games et al.
JOURNAL OF NEUROSCIENCE (2014)
Alpha-synuclein and tau: teammates in neurodegeneration?
Simon Moussaud et al.
MOLECULAR NEURODEGENERATION (2014)
Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5-implications for dementia with Lewy bodies
Cassia R. Overk et al.
MOLECULAR NEURODEGENERATION (2014)
ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo
Brian Spencer et al.
MOLECULAR THERAPY (2014)
Adeno-associated Virus-mediated Delivery of a Recombinant Single-chain Antibody Against Misfolded Superoxide Dismutase for Treatment of Amyotrophic Lateral Sclerosis
Priyanka Patel et al.
MOLECULAR THERAPY (2014)
Brain connectivity in neurodegenerative diseases-from phenotype to proteinopathy
Michela Pievani et al.
NATURE REVIEWS NEUROLOGY (2014)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Extracellular α-Synuclein Leads to Microtubule Destabilization via GSK-3β-Dependent Tau Phosphorylation in PC12 Cells
Magdalena Gassowska et al.
PLOS ONE (2014)
Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1
Pamela Valdes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The A4 Study: Stopping AD Before Symptoms Begin?
Reisa A. Sperling et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease
Eva Kontsekova et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model
Eva Kontsekova et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration
Hien T. Tran et al.
CELL REPORTS (2014)
Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons
Jing L. Guo et al.
CELL (2013)
Determining the Presence of Periodontopathic Virulence Factors in Short-Term Postmortem Alzheimer's Disease Brain Tissue
Sophie Poole et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
α-Synuclein Oligomers Impair Neuronal Microtubule-Kinesin Interplay
Iryna Prots et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Muscle-Directed Anti-Aβ Single-Chain Antibody Delivery via AAV1 Reduces Cerebral Aβ Load in an Alzheimer's Disease Mouse Model
Junling Yang et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2013)
APOE-ε2 and APOE-ε4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature
Peter T. Nelson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
MER5101, a Novel Aβ1-15:DT Conjugate Vaccine, Generates a Robust Anti-Aβ Antibody Response and Attenuates Aβ Pathology and Cognitive Deficits in APPswe/PS1ΔE9 Transgenic Mice
Bin Liu et al.
JOURNAL OF NEUROSCIENCE (2013)
Antisense Reduction of Tau in Adult Mice Protects against Seizures
Sarah L. DeVos et al.
JOURNAL OF NEUROSCIENCE (2013)
Changes in Brain Function Occur Years before the Onset of Cognitive Impairment
Lori L. Beason-Held et al.
JOURNAL OF NEUROSCIENCE (2013)
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
Victor L. Villemagne et al.
LANCET NEUROLOGY (2013)
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice
Michael T. Heneka et al.
NATURE (2013)
The many faces of alpha-synuclein: from structure and toxicity to therapeutic target
Hilal A. Lashuel et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1
Ghanashyam D. Ghadge et al.
NEUROBIOLOGY OF DISEASE (2013)
Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo
Kiran Yanamandra et al.
NEURON (2013)
Monetary Costs of Dementia in the United States
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy
Clara Theunis et al.
PLOS ONE (2013)
Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Elvira Valera et al.
PHARMACOLOGY & THERAPEUTICS (2013)
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia
Tao Zu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia
Changyoun Kim et al.
NATURE COMMUNICATIONS (2013)
Can Intrabodies Serve as Neuroprotective Therapies for Parkinson's Disease? Beginning Thoughts
Mansi A. Bhatt et al.
JOURNAL OF PARKINSONS DISEASE (2013)
Neuropathologic substrates of Parkinson disease dementia
David J. Irwin et al.
ANNALS OF NEUROLOGY (2012)
Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
Megan E. Larson et al.
JOURNAL OF NEUROSCIENCE (2012)
Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific
Wagner Zago et al.
JOURNAL OF NEUROSCIENCE (2012)
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Eun-Jin Bae et al.
JOURNAL OF NEUROSCIENCE (2012)
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
Bengt Winblad et al.
LANCET NEUROLOGY (2012)
Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with α-synuclein at the single molecule level
Georg Nuebling et al.
MOLECULAR NEURODEGENERATION (2012)
Glucose Regulated Protein 78 Diminishes α-Synuclein Neurotoxicity in a Rat Model of Parkinson Disease
Marina S. Gorbatyuk et al.
MOLECULAR THERAPY (2012)
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Charles A. Dinarello et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
OPINION Immunotherapy for Alzheimer disease-the challenge of adverse effects
Yu-Hui Liu et al.
NATURE REVIEWS NEUROLOGY (2012)
Amyloid-β Acts as a Regulator of Neurotransmitter Release Disrupting the Interaction between Synaptophysin and VAMP2
Claire L. Russell et al.
PLOS ONE (2012)
Increased Neuronal α-Synuclein Pathology Associates with Its Accumulation in Oligodendrocytes in Mice Modeling α-Synucleinopathies
Haya Kisos et al.
PLOS ONE (2012)
Frontotemporal Dementia: Implications for Understanding Alzheimer Disease
Michel Goedert et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
Yaroslau Compta et al.
BRAIN (2011)
Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains
Jian-Quan Shi et al.
BRAIN RESEARCH (2011)
FTD and ALS: A Tale of Two Diseases
R. Ferrari et al.
CURRENT ALZHEIMER RESEARCH (2011)
Antibody-based therapy in Alzheimer's disease
Refik Pul et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Pathways towards an effective immunotherapy for Parkinson's disease
Jessica A. L. Hutter-Saunders et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3ß
Fumitaka Kawakami et al.
FEBS JOURNAL (2011)
Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases
David T. Hickman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Induction of Intracellular Tau Aggregation Is Promoted by α-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau
Elisa A. Waxman et al.
JOURNAL OF NEUROSCIENCE (2011)
Vaccination for Parkinson's disease
A. Schneeberger et al.
PARKINSONISM & RELATED DISORDERS (2011)
Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces Aβ Toxicity in a Mouse Model of Alzheimer's Disease
Brian Spencer et al.
PLOS ONE (2011)
Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation
Bobby Thomas et al.
PLOS ONE (2011)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments
David C. Butler et al.
PLOS ONE (2011)
AFFITOME® technology in neurodegenerative diseases The doubling advantage
Achim Schneeberger et al.
HUMAN VACCINES (2010)
Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice
Abigail Snyder-Keller et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2010)
Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors
Kiren Ubhi et al.
JOURNAL OF NEUROSCIENCE (2010)
Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline
Lani K. Clinton et al.
JOURNAL OF NEUROSCIENCE (2010)
Aβ-directed Single-chain Antibody Delivery Via a Serotype-1 AAV Vector Improves Learning Behavior and Pathology in Alzheimer's Disease Mice
Deborah A. Ryan et al.
MOLECULAR THERAPY (2010)
Alzheimer's disease: strategies for disease modification
Martin Citron
NATURE REVIEWS DRUG DISCOVERY (2010)
Cell-to-cell transmission of non-prion protein aggregates
Seung-Jae Lee et al.
NATURE REVIEWS NEUROLOGY (2010)
The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
Stephanie J. Soscia et al.
PLOS ONE (2010)
Protective effect against Parkinson's disease-related insults through the activation of XBP1
Megumi Sado et al.
BRAIN RESEARCH (2009)
Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
Bruno Vellas et al.
CURRENT ALZHEIMER RESEARCH (2009)
α-Synuclein contributes to GSK-3β-catalyzed Tau phosphorylation in Parkinson's disease models
Tetyana Duka et al.
FASEB JOURNAL (2009)
Increased Cerebrospinal Fluid Helicobacter Pylori Antibody in Alzheimer's Disease
Jannis Kountouras et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2009)
ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology
Antero Salminen et al.
JOURNAL OF NEUROINFLAMMATION (2009)
Simvastatin Inhibits the Activation of p21ras and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease
Anamitra Ghosh et al.
JOURNAL OF NEUROSCIENCE (2009)
Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques
M. A. Wozniak et al.
JOURNAL OF PATHOLOGY (2009)
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Paula Desplats et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Clearance and deposition of extracellular α-synuclein aggregates in microglia
He-Jin Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Use of statins and the risk of Parkinson's disease - A retrospective case-control study in the UK
Claudia Becker et al.
DRUG SAFETY (2008)
Statin use and the risk of Parkinson disease: a nested case control study
Ali Samii et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2008)
An scFv intrabody against the nonamyloid component of α-synuclein reduces intracellular aggregation and toxicity
Sandra M. Lynch et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Annett Halle et al.
NATURE IMMUNOLOGY (2008)
Statin use and the risk of Parkinson disease
Angelika D. Wahner et al.
NEUROLOGY (2008)
Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases
Igor F. Tsigelny et al.
PLOS ONE (2008)
Enhanced accumulation of phosphorylated α-synuclein and elevated β-amyloid 42/40 ratio caused by expression of the presenilin-1 ΔT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease
Hiroyuki Kaneko et al.
JOURNAL OF NEUROSCIENCE (2007)
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
Benjamin Wolozin et al.
BMC MEDICINE (2007)
α-synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton
Alessandro Esposito et al.
NEUROBIOLOGY OF DISEASE (2007)
Targeted delivery of proteins across the blood-brain barrier
Brian J. Spencer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
DLB and PDD boundary issues - Diagnosis, treatment, molecular pathology, and biomarkers
C. F. Lippa et al.
NEUROLOGY (2007)
CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
Chad Laurie et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
Structural principles of tau and the paired helical filaments of Alzheimer's disease
Eckhard Mandelkow et al.
BRAIN PATHOLOGY (2007)
Tau protein abnormalities associated with the progression of alzheimer disease type dementia
V. Haroutunian et al.
NEUROBIOLOGY OF AGING (2007)
Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages
Ayodeji A. Asuni et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease
Ken-ichiro Fukuchi et al.
NEUROBIOLOGY OF DISEASE (2006)
Interaction between Aβ peptide and α synuclein:: Molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease
Pravat K. Mandal et al.
NEUROCHEMICAL RESEARCH (2006)
Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E-coli enterotoxin LT(R192G)
M Maier et al.
VACCINE (2005)
β-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease
M Buttini et al.
JOURNAL OF NEUROSCIENCE (2005)
The age-dependent relation of blood pressure to cognitive function and dementia
CX Qiu et al.
LANCET NEUROLOGY (2005)
Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both
ML Kraybill et al.
NEUROLOGY (2005)
Intravesicular localization and exocytosis of α-synuclein and its aggregates
HJ Lee et al.
JOURNAL OF NEUROSCIENCE (2005)
Effects of α-synuclein immunization in a mouse model of Parkinson's disease
E Masliah et al.
NEURON (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
MS Forman et al.
NATURE MEDICINE (2004)
Analysis of α-synuclein-associated proteins by quantitative proteomics
Y Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Molecular pathways to neurodegeneration
E Bossy-Wetzel et al.
NATURE MEDICINE (2004)
Cerebrospinal Fluid Profile of Amyloid beta Peptides in Patients with Alzheimer's Disease Determined by Protein Biochip Technology
Alessia S. Maddalena et al.
NEURODEGENERATIVE DISEASES (2004)
Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases
TE Strandberg et al.
STROKE (2003)
Initiation and synergistic fibrillization of tau and alpha-synuclein
BI Giasson et al.
SCIENCE (2003)
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid
DH Cribbs et al.
INTERNATIONAL IMMUNOLOGY (2003)
Intranasal immunotherapy for the treatment of Alzheimer's disease:: Escherichia coli LT and LT(R192G) as mucosal adjuvants
CA Lemere et al.
NEUROBIOLOGY OF AGING (2002)
Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation
J Wiltfang et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease
JC Augustinack et al.
ACTA NEUROPATHOLOGICA (2002)
Nasal vaccination with β-amyloid peptide for the treatment of Alzheimer's disease
CA Lemere et al.
DNA AND CELL BIOLOGY (2001)
β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
E Masliah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
TAT-mediated protein transduction into mammalian cells
M Becker-Hapak et al.
METHODS (2001)
Synucleinopathies - Clinical and pathological implications
JE Galvin et al.
ARCHIVES OF NEUROLOGY (2001)
14-3-3ζ is an effector of tau protein phosphorylation
M Hashiguchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders
L Buée et al.
BRAIN RESEARCH REVIEWS (2000)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
Dopaminergic loss and inclusion body formation in α-synuclein mice:: Implications for neurodegenerative disorders
E Masliah et al.
SCIENCE (2000)
Share Paper
